Avadel Pharmaceuticals (AVDL) Equity Average: 2009-2022
Historic Equity Average for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Sep 2022 value amounting to -$7.9 million.
- Avadel Pharmaceuticals' Equity Average fell 107.24% to -$7.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$7.9 million, marking a year-over-year decrease of 107.24%. This contributed to the annual value of $120.3 million for FY2021, which is 80.74% up from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Equity Average stood at -$7.9 million, which was down 130.39% from $25.9 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Equity Average ranged from a high of $176.7 million in Q3 2020 and a low of -$28.1 million during Q4 2019.
- Moreover, its 3-year median value for Equity Average was $107.1 million (2020), whereas its average is $91.9 million.
- In the last 5 years, Avadel Pharmaceuticals' Equity Average slumped by 205.75% in 2019 and then soared by 10,317.36% in 2021.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Equity Average stood at $34.3 million in 2018, then plummeted by 181.96% to -$28.1 million in 2019, then skyrocketed by 693.76% to $166.7 million in 2020, then crashed by 46.86% to $88.6 million in 2021, then crashed by 107.24% to -$7.9 million in 2022.
- Its Equity Average was -$7.9 million in Q3 2022, compared to $25.9 million in Q2 2022 and $66.7 million in Q1 2022.